| pubmed-article:2566637 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0001175 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C1882534 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0005149 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0001857 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:2566637 | lifeskim:mentions | umls-concept:C0449435 | lld:lifeskim |
| pubmed-article:2566637 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2566637 | pubmed:dateCreated | 1989-6-30 | lld:pubmed |
| pubmed-article:2566637 | pubmed:abstractText | Abnormally elevated serum beta 2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum beta 2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median beta 2-microglobulin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P = .016). Individual changes in beta 2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r = .42, P = .007). Also, in a randomized placebo-controlled study, median beta 2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P = .05). Serum beta 2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents. | lld:pubmed |
| pubmed-article:2566637 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2566637 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2566637 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2566637 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2566637 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2566637 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:MossAA | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:VolberdingP... | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:WilberJJ | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:BacchettiPP | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:CroweSS | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:HowardWW | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:JacobsonM AMA | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:ChaissonR ERE | lld:pubmed |
| pubmed-article:2566637 | pubmed:author | pubmed-author:AbramsD IDI | lld:pubmed |
| pubmed-article:2566637 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2566637 | pubmed:volume | 159 | lld:pubmed |
| pubmed-article:2566637 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2566637 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2566637 | pubmed:pagination | 1029-36 | lld:pubmed |
| pubmed-article:2566637 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:meshHeading | pubmed-meshheading:2566637-... | lld:pubmed |
| pubmed-article:2566637 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2566637 | pubmed:articleTitle | Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. | lld:pubmed |
| pubmed-article:2566637 | pubmed:affiliation | Department of Medicine, University of California, San Francisco. | lld:pubmed |
| pubmed-article:2566637 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2566637 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2566637 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2566637 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2566637 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2566637 | lld:pubmed |
